Market research
EVG.LSE Evgen Pharma plc
LSE GBP Healthcare
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- P/E ratio
- Not available
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- 1.44
Profile
Instrument facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BSVYN304
- P/E ratio
- Not available
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- 1.44
About
About Evgen Pharma plc
Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Research context
Evgen Pharma plc appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the EVG.LSE discussion.
5 years, 6 months ago
Evgen Pharma plc is currently in a long term downtrend where the price is trading 18.2% below its 200 day moving average.
From a valuation standpoint, the stock is 87.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 54.6.
Its net income has dropped by 0.0% to $-802K since the same quarter in the previous year.
Finally, its free cash flow fell by 16.8% to $-968K since the same quarter in the previous year.
Based on the above factors, Evgen Pharma plc gets an overall score of 1/5.